奈非那韦用于获得性免疫缺陷综合征(艾滋病)与HIV-1感染患者。本品为一非肽类HIV蛋白酶抑制剂，与HIV蛋白酶活性键点可逆性的结合，阻止HIV蛋白酶，影响病毒的终末形成。
辉瑞和FDA也制定了奈非那韦的暂定处方指南。
Pfizer and the FDA have also issued interim prescribing guidelines for Viracept.
药品制造商补充说，EMS杂质在药物生产过程中产生，通常认为是甲磺酸奈非那韦。
The drugmaker added that the EMS impurities were caused by the manufacturing process of the drug, which is known generically as nelfinavir mesylate.
奈非那韦问题于六月份首次发现，当时罗氏公司生产的几批药品被发现EMS水平超标。
Problems with Viracept first came to light in June, when the Roche-manufactured batches were discovered to have excessive levels of EMS.
应用推荐